Innovita Biological Technology Co. Ltd. A
Innovita Biological Technology Co., Ltd., a biopharmaceutical enterprise, engages in the research and development, production and sales of POCT rapid diagnostic products. It offers covid-19 test, respiratory disease test, gastrointestinal disease test, fertility test, tropical disease test, and hepatitis test. The company was founded in 2006 and is based in Beijing, China.
Innovita Biological Technology Co. Ltd. A (688253) - Total Liabilities
Latest total liabilities as of June 2025: CN¥143.21 Million CNY
Based on the latest financial reports, Innovita Biological Technology Co. Ltd. A (688253) has total liabilities worth CN¥143.21 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Innovita Biological Technology Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Innovita Biological Technology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Innovita Biological Technology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Innovita Biological Technology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Chengbang Landscape
SHG:603316
|
China | CN¥1.96 Billion |
|
Shenzhen Fuanna Bedding and Furnishing Co Ltd
SHE:002327
|
China | CN¥1.09 Billion |
|
Kona I Co.Ltd
KQ:052400
|
Korea | ₩292.75 Billion |
|
Better Home & Finance Holding Company
NYSE:BETR
|
USA | $1.16 Billion |
|
Fiera Capital Corporation
PINK:FRRPF
|
USA | $939.81 Million |
|
ADTechnology Co.Ltd
KQ:200710
|
Korea | ₩156.94 Billion |
|
Tibet Aim Pharm Inc
SHE:002826
|
China | CN¥256.63 Million |
|
Guizhou Transp Planning
SHG:603458
|
China | CN¥2.70 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Innovita Biological Technology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovita Biological Technology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovita Biological Technology Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Innovita Biological Technology Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥219.07 Million | -2.05% |
| 2023-12-31 | CN¥223.65 Million | -11.69% |
| 2022-12-31 | CN¥253.24 Million | +324.16% |
| 2021-12-31 | CN¥59.70 Million | -47.67% |
| 2020-12-31 | CN¥114.08 Million | -- |